AMENDMENT No. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
This Amendment to Employment Agreement (the “Amendment”) is entered into as of January 20, 2009 (the “Amendment Effective Date”) by and between OXiGENE, Inc., a Delaware corporation (“OXiGENE”) and David Chaplin, Ph.D., an individual (the “Executive”), and amends the Employment Agreement (the “Agreement”) entered into by and between OXiGENE and Executive as of April 1, 2001 and amended as of January 1, 2007 and December 30, 2008. Pursuant to Section 9 of the Agreement, the Agreement is hereby amended as follows:
AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT among OXiGENE, INC. SYMPHONY ViDA HOLDINGS LLC and SYMPHONY ViDA, INC. Dated as of October 1, 2008Research and Development Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances) • Delaware
This AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of October 1, 2008 (the “Closing Date”) by and among OXiGENE, INC., a Delaware corporation (the “Company”), SYMPHONY ViDA, INC., a Delaware corporation (the “Symphony Collaboration”) (each of the Company and the Symphony Collaboration being a “Party,” and collectively, the “Parties”), and SYMPHONY ViDA HOLDINGS LLC, a Delaware limited liability company (“Holdings”). Capitalized terms used herein and not defined herein shall have the meanings assigned to such terms in Annex A attached hereto.
409A AMENDMENT TO EMPLOYMENT AGREEMENT OF JOHN KOLLINSEmployment Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
WHEREAS, OXiGENE, Inc. (“OXiGENE”) and John Kollins (“Executive”) entered into an employment agreement as of February 28, 2007, as amended (the “Agreement”);
409A AMENDMENT TO EMPLOYMENT AGREEMENT OF PATRICIA WALICKEEmployment Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
WHEREAS, OXiGENE, Inc. (“OXiGENE”) and Patricia Walicke (“Executive”) entered into an employment agreement as of July 31, 2007 (the “Agreement”);
OFFICE LEASE 701 GATEWAY BROADWAY 701 GATEWAY FEE LLC, A DELAWARE LIMITED LIABILITY COMPANY, as Landlord, and OXIGENE, INC. a Delaware corporation, (NASDAQ Listing Symbol: OXGN) as Tenant.Office Lease • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
RESEARCH AND DEVELOPMENT AGREEMENT between OXiGENE, INC. and SYMPHONY ViDA HOLDINGS LLC Dated as of October 1, 2008Research and Development Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances) • Delaware
This RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of October 1, 2008 (the “Closing Date”) by and between OXiGENE, INC., a Delaware corporation (the “Company”) and SYMPHONY ViDA HOLDINGS LLC, a Delaware limited liability company (“Holdings”) (each of the Company and Holdings being a “Party,” and collectively, the “Parties”). Capitalized terms used herein and not defined herein shall have the meanings assigned to such terms in Annex A attached hereto.
AMENDMENT No. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
This Amendment to Employment Agreement (the “Amendment”) is entered into as of January 20, 2009 (the “Amendment Effective Date”) by and between OXiGENE, Inc., a Delaware corporation (“OXiGENE”) and James B. Murphy, an individual (the “Executive”), and amends the Employment Agreement (the “Agreement”) entered into by and between OXiGENE and Executive as of February 23, 2004 and amended as of December 30, 2008. Pursuant to Section 9 of the Agreement, the Agreement is hereby amended as follows:
409A AMENDMENT TO EMPLOYMENT AGREEMENT OF DR. DAVID CHAPLINEmployment Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
WHEREAS, OXiGENE, Inc. (“OXiGENE”) and Dr. David Chaplin (“Executive”) entered into an employment agreement as of April 1, 2001 as amended (the “Agreement”);
409A AMENDMENT TO EMPLOYMENT AGREEMENT OF JAMES B. MURPHYEmployment Agreement • March 30th, 2009 • Oxigene Inc • Biological products, (no disgnostic substances)
WHEREAS, OXiGENE, Inc. (“OXiGENE”) and James B. Murphy (“Executive”) entered into an employment agreement as of February 23, 2004 (the “Agreement”);
